Oasmia's patented XR-17 technology generates novel cancer combination therapy
Oasmia Pharmaceutical ABCompany AnnouncementOasmia's patented XR-17 technology generates novel cancer combination therap…
Oasmia Pharmaceutical ABCompany AnnouncementOasmia's patented XR-17 technology generates novel cancer combination therap…
Oasmia Pharmaceutical AB and Orion Corporation jointly agreed to end the agreement regarding distribution of Paclical® i…
Oasmia Pharmaceutical AB (ISIN SE0000722365), ein innovatives Pharmaunternehmen mit neuartigen Wirkstoffentwicklungen i…
The agreement concerns license- and distribution rights to Oasmia's pharmaceutical candidate Paclical® in Israel and Tur…
Oasmia Pharmaceutical AB (ISIN SE0000722365), ein innovatives Pharmaunternehmen mit neuartigen Wirkstoffentwicklungen i…